J&J - Study in Mcspc Demonstrated That Erleada(®) Reduced Risk of Death by 23 Percent at 24 Months Compared to Enzalutamide
J&J - Mcspc研究表明,與恩扎魯胺相比,Erleada(®)在24個月內將死亡風險降低了23%
J&J - Study in Mcspc Demonstrated That Erleada(®) Reduced Risk of Death by 23 Percent at 24 Months Compared to Enzalutamide
J&J - Mcspc研究表明,與恩扎魯胺相比,Erleada(®)在24個月內將死亡風險降低了23%
譯文內容由第三人軟體翻譯。